

Esophageal Cancer Cases

Quiz Questions:

Relationship between proto-oncogene and oncogene?

Examples:

Ras

HER2/neu

MYC

Tumor Suppressor Genes

FAP Prophylactic Surgery

- Total proctocolectomy with ileoal pouch
- Total colectomy with ileorectal anastomosis
- Proctocolectomy with end ileostomy

Lynch Syndrome Prophylactic Surgery

- No role for prophylactic colon surgery
- Prophylactic hysterectomy with BSO

BRCA 1/2 Prophylactic Surgery

- Bilateral mastectomy reduces lifetime risk 90%
- Surveillance is a reasonable option
 - Yearly mammogram
 - Yearly breast MRI

BRAC 1/2 Prophylactic Surgery

- Prophylactic BOS age 35-40 or after childbearing
- Reduces risk of ovarian cancer 80%
- Surveillance not as effective
 - Transvaginal ultrasound
 - CA-125 screening

MEN 2A/2B or FMTC Prophylactic surgery

- Timing of thyroidectomy depends upon risk category
- Highest risk: Thyroidectomy within first year of life
- High risk: Thyroidectomy by age 5 or if calcitonin elevated
- Moderate risk: surveillance starting age 5
 - physical exam
 - neck ultrasound
 - serum calcitonin

FAP

Median age of dx 39

- Duodenal and ampullary tumors
- Gastric polyps
- Thyroid tumors
- Desmoid tumors

FAP screening

Colonoscopy age 10-12 EGD for duodenal polyps at age 20-30
CT 1-3 years after colectomy and q5 yers in those with family
hx of desmoids

Lynch

Amdterdam Criteria

(Bethesda Criteria)

Mean age dx colon cancer 44-61 Predominant right side colon
cancer Lifetime penetrance 82%

Lynch Other Cancers

- Endometrial
- Stomach
- Ovarian
- Urinary tract
- Biliary Tract
- Small bowel
- CNS

Lynch Screening

Colonoscopy q1-2 years staring age 20-25

Women with Lymch have 25-60% lifetime risk of endometrial
cancer 45-12% lifetime risk of ovarian cancer Male: 1.2% risk
of breast cancer (0.1% in general populations)

MMR and MSI

Greater than 90% of LS tumors are MSI-high (MSI-H) and/or lack expression of at least one of the MMR proteins by IHC. Ten percent to 15% of sporadic colon cancers exhibit abnormal IHC and are MSI-H most often due to abnormal methylation of the MLH1 gene promoter, rather than due to LS. Mutant BRAF V600E is found in many sporadic MSI-H CRCs and is rarely found in LS-related CRCs. There are some tumors that will have MLH1 methylation but lack a BRAF PV.

DNA Mismatch Repair Proteins



DNA Mismatch Repair Proteins

MLH1 PMS1 MSH6 MSH2 MSH5



DNA Mismatch Repair Proteins



Mismatch Repair Proteins in Lynch Syndrome

Lynch Syndrome can be caused by loss of expression of:

- MLH1
- PMS1
- MSH6
- MSH2
- MSH5

MLH1 and PMS Dimer in Mismatch Repair

wild-type MLH1 and PMS2 form a stable heterodimer



MLH1 and PMS Dimer in Mismatch Repair

Mutant MLH1 fails to form a stable heterodimer



MLH1 and PMS Dimer in Mismatch Repair

Mutant MLH1 fails to form a stable heterodimer → PMS2 is degraded



MLH1 and PMS Dimer in Mismatch Repair

If MLH1 is mutated → PMS2 protein is *not* detected



Colon Polyposis: >10 adenomatous polyps

- Classical FAP
- Attenuated FAP (AFAP)
- MUTYH-associated polyposis (MAP)
- Colonic adenomatous polyposis of unknown etiology (CPUE)

Colon Polyposis: >4 hamartomatous polyps

- Puetz-Jaghers
- Juvenile Polyposis Syndrome
- Cowden Syndrome/PTEN Hamartoma Tumor Syndrome

Serrated Colon Polyps

5 serrated polyps/lesions proximal to the rectum, all being 5 mm in size, with 2 being 10 mm in size OR >20 serrated polyps/lesions of any size distributed throughout the large bowel, with 5 being proximal to the rectum

Muir-Torre Syndrome

Muir-Torre syndrome refers to individuals with LS who have LS-associated skin findings of sebaceous adenomas/carcinomas or keratoacanthomas.

BRCA 1/2

BRCA1: 87% lifetime risk of breast cancer and 40-60% risk of ovarian cancer

BRCA2: 80% lifetime breast cancer and 15-27% ovarian cancer
- Elevated risk of prostate, pancreas, melanoma

Male carriers of BRCA2: 8.9% lifetime risk of breast cancer

BRCA risk factors:

- Breast cancer dx before age 40
- Bilateral breast cancer
- Breast and ovarian cancer
- 2 family members with breast cancer < age 50
- Family history of breast and ovarian
- Family history of male breast cancer

Attenuated FAP

~30 polyps 70% penetrance by age 80 - mean age at dx 50-55

Li-Fraumeni

Mutation of TP53 tumor suppressor gene

- Breast cancer 90% by age 50
- Sarcoma
- Leukemia
- Brain tumors
- Adrenocortical carcinoma

Breast cancer in Li-Fraumeni

Mastectomy favored to avoid radiation therapy

Bilateral prophylactic mastectomy recommended

p16 = CDKN2A mutation

- Increased risk of melanoma
 - Familial Atypical Multiple Mole Melanoma (FAMMM)
 - Familial Atypical Multiple Mole-Pancreatic Carcinoma (FAMMMPC)
- Melanoma penetrance 58-92% by 80
- Pancreatic cancer penetrance 17% by age 75

FAMMM

- Malignant melanoma in one or more first degree or second-degree relatives
- High total body nevus count
- Nevi with certain features on microscopy

Genetic testing not performed as only 50% of FAMMM harbor a mutation in CDKN2A

Neurofibromatosis 1

Mutation in NF1 tumor suppressor gene

- Multiple neurofibromas
- Cafe au lait spots
- Lisch nodules (hamartoma of the iris)

Risk of - NPNST - Pheochromocytoma - Astrocytoma - Leukemia

NF1 diagnosis

Two or more of the following 6 criteria:

- Six or more café-au-lait macules
- Two or more neurofibromas or one plexiform neurofibroma
- Axillary or inguinal freckling
- Optic glioma
- Two or more Lisch nodules
- Characteristic osseous lesions
- A first degree relative with NF1

Neurofibromatosis 2

NF2 gene

- Multiple neurofibromas
- Cafe au lait spots
- Bilateral vestibular schwannomas
- CNS tumors

Most affected develop bilateral schwannomas by age 30 with average age of death 26

Annual surveillance MRI starting age 10-12 and hearing evaluation

PTEN

Cowden Syndrome Mutation in *PTEN* tumor suppressor gene

- Mucocutaneous facial lesions
- Macrocephaly
- Bilateral breast cancer
- Thyroid and endometrial tumors
- Hamartomatous polyposis of the GI tract

MEN1

- Mutation of MENIN tumor suppressor
- Parathyroid
- Pituitary
- Pancreatic islet cells

Hyperparathyroidism usually first presentation Most common pancreatic tumor is non-functional

Dx by 2/3 of following:

- Parathyroid adenoma/hyperplasia
- Pancreatic islet cell tumors
- Pituitary tumors

MEN1 screening

Surveillance with serum prolactin, IGF-1, fasting glucose and insulin starting age 5 Calcium, chormogranin A, pancrea polypeptide glucagon AP age 8 Serum gastrin starting age 20 Brain MRI starting age 5 Abdominal CT/MRI starting age 20

MEN1 surgical treatment

Parathyroidectomy 3.5 gland or 4 glands with autotransplantation

Pancreatic tumor resection if >2cm

Pituitary tumors resected via transsphenoidal

MEN2 Family of Syndromes

- RET proto-oncogene
- Medullary thyroid cancer in almost 100%
- MEN2A
 - pheochromocytoma in 50%
 - Parathyroid hyperplasia in 20-30%

-MEN2B - pheochromocytoma in 50% - Megacolon - Marfanoid habitus - Ganglioneuromas - Mucosal neuromas

MEN 2 Prophylactic surgery

Prophylactic total thyroidectomy

Testing for pheochromocytoma prior with adrenalectomy

Monitor calcitonin and CEA after thyroidectomy

Orientation Handbook



References